TSX:BLU (Bellus Health)
About BLU
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Bellus Health (TSX: BLU) Latest News
Investing
3 Growth Stocks up Over 50% in 2022

Dividend Stocks
3 Stocks To Keep Your Retirement Savings Growing Faster Than Inflation

Page
Top Biotech Stocks in Canada of 2025

Investing
3 Simple TSX Stocks to Buy With $25 Right Now
Investing
TFSA Investors: 3 Stocks That Haven’t Lost Money in 2022
Investing
Parabolic Returns in 2022 Are Possible From 3 Growth Stocks

Coronavirus
Is Bellus Health Stock Still a Buy After 30% Earnings Jump?
